substrate reduction

Substrate Reduction Therapy ABX1100 Named FDA Orphan Drug

ABX1100, an experimental substrate reduction therapy that Aro Biotherapeutics is developing for Pompe disease, has been granted an orphan drug designation by the U.S. Food and Drug Administration (FDA). The FDA gives this designation to investigational treatments designed to improve care for rare diseases affecting fewer than…

First Healthy Volunteers Dosed in Trial of Oral Therapy MZE001

The first healthy volunteers have been dosed in a Phase 1 clinical trial evaluating MZE001, Maze Therapeutics’ experimental oral therapy for Pompe disease. “The initiation of this study is a significant milestone for both Maze and the Pompe community as we advance into the clinic with a potentially…

Maze Raises $190M, Gears Up for First Clinical Testing of MZE001

Maze Therapeutics has announced its plans to begin clinical testing of MZE001, its lead candidate therapy for Pompe disease, in the first half of this year. The California-based precision medicine company raised $190 million in financing — led by Matrix Capital Management — to support the development of…